# Sun Pharmaceutical Industries on Monday announced the $11.75 billion acquisition of Organon & Co. US contributes about 31% of Sun’s revenues, second only to the Indian domestic market bringing 37%.

*biotech · news · 2026-04-28 · Hindustan Times*

## Key points

- Sun Pharma's $11.75 billion Organon acquisition is the largest Indian pharma deal in two decades.
- The combined entity’s US revenue share drops to 27%, while India’s share falls to 17%.
- The acquisition targets geographic diversification, notably expanding Sun Pharma's presence in China and South Korea.
- Sun Pharma gains immediate access to Organon's scale in Spain and branded generics portfolios for cross-selling.
- The US generics market is declining in profitability due to pricing pressure and structural shift toward biologics.

**Companies:** Sun Pharmaceutical Industries, Organon & Co.
**Countries:** India, United States, China, South Korea, Spain

[Read the full story on Hindustan Times](https://www.hindustantimes.com/business/winds-of-change-in-sun-pharmas-11-75-billion-organon-acquisition-announcement-101777344404880.html)

---

Canonical: https://newsio.io/n/bb964634-b55a-40f4-a915-6241d61d926d/sun-pharmaceutical-industries-on-monday-announced-the-11-75-billion-acquisition
Summarized by Newsio from Hindustan Times. https://newsio.io/how-it-works